Skip to main content
Journal cover image

Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants.

Publication ,  Journal Article
Gallagher, JL; Patel, NC
Published in: J Clin Immunol
June 2012

Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than 2 years of age. We report two infants less than 2 years in which administration of Hizentra® was safe and effective.

Duke Scholars

Published In

J Clin Immunol

DOI

EISSN

1573-2592

Publication Date

June 2012

Volume

32

Issue

3

Start / End Page

474 / 476

Location

Netherlands

Related Subject Headings

  • Turner Syndrome
  • Netherton Syndrome
  • Injections, Subcutaneous
  • Infant
  • Immunology
  • Immunoglobulin G
  • Immunization, Passive
  • Humans
  • Female
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gallagher, J. L., & Patel, N. C. (2012). Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants. J Clin Immunol, 32(3), 474–476. https://doi.org/10.1007/s10875-011-9645-0
Gallagher, Joel L., and Niraj C. Patel. “Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants.J Clin Immunol 32, no. 3 (June 2012): 474–76. https://doi.org/10.1007/s10875-011-9645-0.
Gallagher, Joel L., and Niraj C. Patel. “Subcutaneous immunoglobulin replacement therapy with Hizentra® is safe and effective in two infants.J Clin Immunol, vol. 32, no. 3, June 2012, pp. 474–76. Pubmed, doi:10.1007/s10875-011-9645-0.
Journal cover image

Published In

J Clin Immunol

DOI

EISSN

1573-2592

Publication Date

June 2012

Volume

32

Issue

3

Start / End Page

474 / 476

Location

Netherlands

Related Subject Headings

  • Turner Syndrome
  • Netherton Syndrome
  • Injections, Subcutaneous
  • Infant
  • Immunology
  • Immunoglobulin G
  • Immunization, Passive
  • Humans
  • Female
  • 3204 Immunology